Tumor necrosis factor (TNF) inhibitors have been widely used for the treatment of autoimmune disease since 1998, when the first biological agents were licensed in the United States.¹ Several biosimilar versions are now available.² These therapies target the TNF receptor (infliximab, adalimumab, certolizumab pegol, and golimumab) or its soluble form (etanercept) to modulate immune function.

中文翻译：

---

肿瘤坏死因子抑制剂治疗的神经炎性不良事件的风险。

自1998年第一批生物制剂在美国获得许可以来，肿瘤坏死因子（TNF）抑制剂已广泛用于治疗自身免疫性疾病。¹现在有几种生物仿制药版本。²这些疗法靶向TNF受体（英夫利昔单抗，阿达木单抗，西妥珠单抗和戈利木单抗）或其可溶形式（依那西普）来调节免疫功能。